

	<ul style="list-style-type: none"> • Izabela Syrek, Administrator 	<ul style="list-style-type: none"> • Present for all items
External assessment centre (EAC) representatives present:	<ul style="list-style-type: none"> • Dr Susan O'Connell, Senior Researcher, Cedar • Ms Megan Dale, Researcher, Cedar 	<ul style="list-style-type: none"> • Present for items 1-8 • Present for items 1-8
Expert advisers present	<ul style="list-style-type: none"> • Dr Ben Wakerley, Neurology Consultant, Gloucester Royal Hospital, Gloucestershire Hospital NHS Foundation Trust • Dr Brendan Davies, Consultant Neurologist, Royal Stoke University Hospital, University Hospitals of North Midlands NHS Trust 	<ul style="list-style-type: none"> • Present for items 1-8 • Present for items 1-8
Non-public present:	<ul style="list-style-type: none"> • Tara Chernick, Health Technology Adoption Manager, Adoption and Impact Team, NICE • Ian Mather, Business Analyst, Resource Impact Assessment Team, NICE • Helen Crosbie, Public Involvement Adviser, Public Involvement Team, NICE • Ann Greenwood, Senior Medical Editor, Publishing Team, NICE • Emilene Coventry, Senior Medical Editor, Publishing Team, NICE 	<ul style="list-style-type: none"> • Present for items 1-10 • Present for items 1-10 • Present for items 1-10 • Present for items 1-10 • Present for items 1-10

Introduction to the meeting

1. The chair welcomed all members of the committee and other attendees present to the meeting.

News and announcements

2. The chair offered news and announcements, and noted committee members who had given apologies for the meeting.

Minutes of previous meeting

3. The committee agreed the minutes from the 22nd March 2019 committee meeting.

MT323 gammaCore for cluster headache

Part 1 – Open session

4. The chair welcomed the invited experts, external assessment centre representatives, members of the public and company representatives from electroCore. The chair

then explained the code of conduct to the members of the public observing the meeting.

5. The chair asked all committee members, experts, NICE staff and observers to declare any relevant interests in relation to the technology being considered.
 - Dr Brendan Davies declared a non-financial professional interest ahead of the meeting as he is a co-author on a published paper in the journal of Headache and Pain on the real-world use of the gammaCore device for the treatment of 30 patients with cluster headache in the UK. The paper has been published in November 2018.

Dr Brendan Davies declared an indirect interest as well ahead of the meeting as he is currently acting as a UK principal investigator in commercial study of Galcanezumab, an anti-CGRP monoclonal antibody vs. placebo as a potential treatment for cluster headache.

- It was agreed that his declarations would not prevent Dr Davies from providing expert advice to the committee.
- Dr Benjamin Wakerley declared an indirect interest ahead of the meeting as he runs the Oxford headache symposium, an annual non-profit making headache meeting that has been hosted in Oxford. Dr Wakerley has organised the meeting since 2016 and it is attended by neurologists, GPs and nurses with specialist interest in headache. Typically, the event is sponsored by other pharmaceutical companies related to headache – e.g. Allergan, Novartis, Cefaly.
 - It was agreed that his declarations would not prevent Dr Wakerley from providing expert advice to the committee.

No other interests were declared.

6. The committee was asked if there were any specific equality issues to consider in relation to the technology being considered.
7. The topic was introduced by Dr Paul Knox and Dr Teik Goh, with Dr Ben Wakerley and Dr Brendan Davies providing expert advice.
8. The chair thanked the experts, external assessment centre representatives, members of the public and company representatives for their attendance and they left the meeting.

Part 2 – Closed session

9. The committee then proposed draft recommendations on the technology and these recommendations were reached by consensus.

Date of the next meeting

10. The next meeting of the medical technologies advisory committee will be held on Friday 13 September 2019 and will start promptly at 10:00am. The meeting will be held at the NICE Manchester offices, Level 1A City Tower, Piccadilly Plaza, Manchester M1 4BT.